$PCVX News

Vaxcyte: Vaccine Titan In The Making

Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a Bet

Cantor Fitzgerald Reiterates Overweight on Vaxcyte, Announces $120 Price Target

Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior Notes

Why Vaxcyte (PCVX) Is Getting Attention Again

Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes

As Expected: Vaxcyte Announces $1 Billion Stock and Convertible Raise a Day After Its Phase 3 Win (and Sinks 10%)

Vaxcyte’s VAX-31 Meets All Primary Endpoints in Pivotal Phase III OPUS-1 Trial

Vaxcyte stock falls on $1B dual offering launch

Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes

PCVX Stock Hits Fresh 52-Week High On Late-Stage Win In Adult Pneumonia Vaccine Race: Jefferies Says It Hit ‘Blue-Sky’ Case

Vaxcyte Stock Spikes 27% as Lead Vaccine Candidate Takes Aim at Pfizer and Merck

Vaxcyte Soars 36% on Phase 3 Pneumococcal Vaccine Win That “Sets a New Benchmark”

Vaxcyte’s stock up after pneumococcal vaccine proves non-inferiority

Vaxcyte shares surge on late-stage vaccine trial success

Vaxcyte Catapults After Going Toe-To-Toe With Pfizer, Merck In Vaccine Study

Vaxcyte skyrockets on ‘near best-case’ pneumococcal vaccine data

Vaxcyte, Inc. (PCVX) Discusses Top Line Results From OPUS-1 Phase 3 Trial of VAX-31 Pneumococcal Vaccine Candidate Transcript

BTIG Reiterates Buy on Vaxcyte, Maintains $89 Price Target

Needham Maintains Buy on Vaxcyte, Raises Price Target to $122